Security key
87650L103
Tarsus Pharmaceuticals, Inc. - Common Stock (TARS)
CUSIP: 87650L103
Q3 2022 13F Holders as of 30 Sep 2022
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 20,489,091
- Total 13F value
- $350,771,070
- Share change
- +508,341
- SEC-reported price per share
- $17.12
- Number of holders
- 72
- Value change
- +$9,266,431
- Number of buys
- 34
- Number of sells
- 27
- Shares outstanding
- 42,282,321
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2022
Institutions
72
Top holders
10
TARS full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2022
Previous quarter: Q2 2022
Tarsus Pharmaceuticals, Inc. SEC filings
Tarsus Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 87650L103
Recent filing periods:
Ownership snapshot
Top reported holders of TARS - Tarsus Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Vivo Capital, LLC
Disclosed value leader
RTW INVESTMENTS, LP
Comparable rows
15/15
Latest evidence
30 Jun 2022
13F
3/4/5
Lead comparable stake: 5.5%
Showing 1-6 of 15 holder rows.
Quick read
Vivo Capital, LLC leads the comparable SEC ownership view at 5.5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Vivo Capital, LLC's linked filing trail.
Comparable ownership
Top 5
Vivo Capital, LLC
5.5%
TANG CAPITAL MANAGEMENT LLC
4.9%
RTW INVESTMENTS, LP
4.8%
Cormorant Asset Management, LP
4.4%
Frazier Life Sciences Management,...
4.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Vivo Capital, LLC |
13F
Company
|
5.5%
|
$33,761,000
2,312,368 shares
|
— | 30 Jun 2022 |
| TANG CAPITAL MANAGEMENT LLC |
13F
Company
|
4.9%
|
$30,432,000
2,084,370 shares
|
— | 30 Jun 2022 |
| RTW INVESTMENTS, LP |
3/4/5
13F
10%+ Owner · Company
|
4.8%
from 13F
|
$40,272,020
2,013,601 shares
|
— | 07 May 2021 |
| Cormorant Asset Management, LP |
13F
Company
|
4.4%
|
$27,375,000
1,875,000 shares
|
— | 30 Jun 2022 |
| Frazier Life Sciences Management, L.P. |
13F
Company
|
4.2%
|
$26,098,000
1,787,527 shares
|
— | 30 Jun 2022 |
| TimesSquare Capital Management, LLC |
13F
Company
|
3.5%
|
$21,633,000
1,481,710 shares
|
— | 30 Jun 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2022
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
72
Shares
20,489,091
Rows available
72
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2022 vs Q2 2022 Across Filers
Q2 2022 holders
70
Q3 2022 holders
72
Holder diff
2
| Investor | Q2 2022 Shares | Q3 2022 Shares | Share Diff | Share Chg % | Q2 2022 value | Q3 2022 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend